|
$386,386
|
To research Medicaid spending on prescription drugs under the Food and Drug Administration's accelerated approval pathway with unclear clinical benefits.
|
2020 - 2023
|
LJAF
|
|
$280,385
|
To provide stakeholders with transparent information about Food and Drug Administration approved and experimental medications.
|
2020 - 2022
|
LJAF
|
|
$359,808
|
To advance the implementation and rigorous testing of deferred prosecution programs.
|
2016 - 2018
|
LJAF
|
